100 related articles for article (PubMed ID: 10682137)
1. Quantitative p24 antigenaemia for monitoring response to antiretroviral therapy in HIV-1 group O-infected patients.
Machuca A; Gutiérrez M; Mur A; Soriano V
Antivir Ther; 1998; 3(3):187-9. PubMed ID: 10682137
[TBL] [Abstract][Full Text] [Related]
2. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
[TBL] [Abstract][Full Text] [Related]
3. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
Rezza G; Galai N; Pezzotti P; Vlahov D; Graham NM; Viale P; Angarano G
Antivir Ther; 1997 Jul; 2(3):167-74. PubMed ID: 11322271
[TBL] [Abstract][Full Text] [Related]
4. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
[TBL] [Abstract][Full Text] [Related]
5. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA.
Schüpbach J
AIDS Rev; 2002; 4(2):83-92. PubMed ID: 12152521
[TBL] [Abstract][Full Text] [Related]
6. Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease.
Sterling TR; Hoover DR; Astemborski J; Vlahov D; Bartlett JG; Schupbach J
J Infect Dis; 2002 Oct; 186(8):1181-5. PubMed ID: 12355373
[TBL] [Abstract][Full Text] [Related]
7. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays.
de Mendoza C; Lu W; Machuca A; Sainz M; Castilla J; Soriano V
J Med Virol; 2001 Jul; 64(3):217-22. PubMed ID: 11424107
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia.
Alexander CS; Montessori V; Wynhoven B; Dong W; Chan K; O'Shaughnessy MV; Mo T; Piaseczny M; Montaner JS; Harrigan PR
Antivir Ther; 2002 Mar; 7(1):31-5. PubMed ID: 12008785
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement.
Ledergerber B; Flepp M; Böni J; Tomasik Z; Cone RW; Lüthy R; Schüpbach J
J Infect Dis; 2000 Apr; 181(4):1280-8. PubMed ID: 10751136
[TBL] [Abstract][Full Text] [Related]
12. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
13. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
[TBL] [Abstract][Full Text] [Related]
14. [Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)].
Miró JM; Antela A; Arrizabalaga J; Clotet B; Gatell JM; Guerra L; Iribarren JA; Laguna F; Moreno S; Parras F; Rubio R; Santamaría JM; Viciana P
Enferm Infecc Microbiol Clin; 2000; 18(7):329-51. PubMed ID: 11109725
[TBL] [Abstract][Full Text] [Related]
15. Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline.
Lange JM; de Wolf F; Krone WJ; Danner SA; Coutinho RA; Goudsmit J
AIDS; 1987 Sep; 1(3):155-9. PubMed ID: 3126756
[TBL] [Abstract][Full Text] [Related]
16. Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report.
Capiluppi B; Saracco A; Gianotti N; Mussini C; Butini L; Tomasoni L; De Gennaro M; Rizzolo L; Monolo G; Cargnel A; Moioli C; Arici C; Portelli V; Rizzardini G; Lazzarin A; Tambussi G
J Biol Regul Homeost Agents; 2002; 16(1):73-8. PubMed ID: 12003179
[TBL] [Abstract][Full Text] [Related]
17. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
18. Quantification of HIV-1 p24 by a highly improved ELISA: an alternative to HIV-1 RNA based treatment monitoring in patients from Abidjan, Côte d'Ivoire.
Tehe A; Maurice C; Hanson DL; Borget MY; Abiola N; Maran M; Yavo D; Tomasik Z; Böni J; Schüpbach J; Nkengasong JN
J Clin Virol; 2006 Nov; 37(3):199-205. PubMed ID: 16973409
[TBL] [Abstract][Full Text] [Related]
19. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
[TBL] [Abstract][Full Text] [Related]
20. The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study.
DeHovitz JA; Kovacs A; Feldman JG; Anastos K; Young M; Cohen M; Gange SJ; Melnick S; Greenblatt RM
J Infect Dis; 2000 Nov; 182(5):1527-30. PubMed ID: 11010840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
